Anti-WNT (clone W24V25) Recombinant Antibody Coupled Liposome (VS-1024-FY26) (CAT#: VS-1024-FY26)

The application of anti-Wnt antibody-conjugated liposomes in human colorectal cancer is an active area of research. Studies have shown that liposomal drugs can specifically interfere with the aberrant Wnt signaling pathways in tumor tissues, which has a targeted effect on tumor stem cells (LGR5+ CSCs). This strategy may be translated into clinical applications in the future, potentially helping to improve treatment outcomes for colorectal cancer.
Anti-Wnt antibody conjugated liposomes hold significant potential in Adrenocortical carcinoma (ACC) research by specifically targeting Wnt signaling pathways, which are often dysregulated in cancer progression. These liposomes can enhance the delivery of therapeutic agents directly to tumor cells, improving the efficacy and specificity of treatment while minimizing off-target effects. Additionally, the conjugation of anti-Wnt antibodies can facilitate the monitoring of treatment response through imaging techniques, providing valuable insights into tumor dynamics.